Sugi Predict

Sugi Predict / Compounds / SCHEMBL3197488

SCHEMBL3197488

SCHEMBL3197488

Cc1ccc(NC(=O)Nc2cccc(CN3CCN(S(=O)(=O)C4CC4)[C@H](C)C3)c2F)cn1

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 8/20 0.43
▸ DHODH Q02127 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CCR3 P51677 5/20 0.38
▸ MAPK8 P45983 2/20 0.38
▸ MAPK10 P53779 2/20 0.38
▸ KCNH2 Q12809 2/20 0.38
▸ SIRT2 Q8IXJ6 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3189536 0.91 RORC (0.42) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3196559 0.91 RORC (0.42) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3205533 0.91 RORC (0.42) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3206229 0.91 RORC (0.42) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3208746 0.90 RORC (0.41) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3197767 0.90 RORC (0.41) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3203521 0.90 RORC (0.41) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3196600 0.90 RORC (0.41) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3206541 0.89 RORC (0.42) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3197657 0.88 SIRT2 (0.38) RORCDHODHNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1959960-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2008-08-27 — — EP claimed
WO-2007070683-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2007-06-21 — — WO claimed
US-8871768-B2 Certain chemical entities, compositions and methods CYTOKINETICS, INC. (US) 2014-10-28 — — US disclosed
US-20130324549-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2013-12-05 — — US disclosed
US-8445495-B2 Certain Chemical entities, compositions and methods CYTOKINETICS, INC. (US) 2013-05-21 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 RORC 2972/4885DHODH 3762/4885NPC1 4691/4885
US-20130324549-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS TNNI3, TNNT2, MYLK2 RORC 2972/4885DHODH 3762/4885NPC1 4691/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 RORC 2972/4885DHODH 3762/4885NPC1 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.